Farther Finance Advisors LLC Purchases 207 Shares of Cencora, Inc. (NYSE:COR)

Farther Finance Advisors LLC raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 15.2% in the second quarter, Holdings Channel reports. The institutional investor owned 1,569 shares of the company’s stock after acquiring an additional 207 shares during the period. Farther Finance Advisors LLC’s holdings in Cencora were worth $351,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in COR. Vanguard Group Inc. bought a new position in Cencora during the fourth quarter valued at $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Cencora in the 1st quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. purchased a new position in shares of Cencora in the 1st quarter worth approximately $1,199,695,000. Boston Partners acquired a new stake in Cencora in the 1st quarter worth approximately $1,001,269,000. Finally, Capital Research Global Investors acquired a new stake in Cencora in the 1st quarter worth approximately $650,424,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on COR. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird raised their price objective on shares of Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $258.63.

Cencora Stock Down 0.1 %

NYSE COR opened at $243.36 on Thursday. The stock has a market cap of $48.54 billion, a PE ratio of 26.63, a P/E/G ratio of 1.57 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The business has a 50 day moving average price of $232.08 and a two-hundred day moving average price of $233.16. Cencora, Inc. has a fifty-two week low of $171.65 and a fifty-two week high of $247.66.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same period last year, the company earned $2.92 earnings per share. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, sell-side analysts predict that Cencora, Inc. will post 13.61 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a $0.51 dividend. The ex-dividend date was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.84%. Cencora’s dividend payout ratio (DPR) is 22.32%.

Insider Activity at Cencora

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799. Corporate insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.